CD33 and acute myeloid leukemia: Although NK cell activity is impaired in AML [43,47,48,49,87], preclinical data has shown enhanced response and NKG2D ligand upregulation on combining decitabine with an anti-CD33 Fc-optimized antibody BI 836858 [88].